Zenas BioPharma, Inc. (ZBIO)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
24. 84
-0.56
-2.2047%
$
1.72B Market Cap
- P/E Ratio
- Div Yield
661,700 Volume
- Eps
$ 25.4
Previous Close 
Want to track ZBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials
Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab, although the final figure may differ. The company is developing antibody-based treatments for inflammatory disorders, with strong backing from well-known life science venture capital firms and Bristol-Myers Squibb. Zenas' lead candidate, obexelimab, has shown promising Phase 2 results and is currently enrolling in a global Phase 3 trial for IgG4-related diseases.
Seekingalpha | 2 years ago
2026 © Marketlog. All Rights Reserved.
